Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Apomivir
- Development stage
- Phase 2
- Lead developer
- Far East Bio-Tec
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Apomivir is a botanical antiviral drug candidate derived from a proprietary strain of the blue-green algae *Arthrospira platensis* (spirulina), specifically the FEM-101 strain. Developed by Far East Bio-Tec Co., Ltd. (FEBICO), it is produced using a patented freeze-thaw lysis and extraction method. Preclinical studies have demonstrated that Apomivir possesses broad-spectrum antiviral activity, with particular efficacy against seasonal influenza A and B viruses. The drug is thought to inhibit viral entry and replication. It has been evaluated in Phase 2 clinical trials for its safety and efficacy in relieving symptoms of seasonal influenza.
- Brand names
- Apomivir
- Other names
- ApomivirFEM-101 extractFEM101 extractFEM 101 extract
Beyond the preview
Go deeper on Apomivir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apomivir.